Key result
In patients with aneurysmal subarachnoid hemorrhage, 49% were switched to a nonstandard nimodipine regimen (30 mg every 2 h), with vasospasm (OR 5.30) and vasopressor therapy (OR 3.29) significantly increasing the odds of this manipulation.
Why the study?
What is the incidence of and factors associated with switching to a nonstandard nimodipine dosing regimen in patients with aneurysmal subarachnoid hemorrhage?
Population
166 patients receiving nimodipine for aneurysmal subarachnoid hemorrhage at a tertiary care teaching…
Comparison
Switch to nonstandard nimodipine dosing regimen vs Continuation of standard nimodipine dosing
Design
Cohort
Authors
Loading...
Common nimodipine regimen switches in aSAH warrant caution; leaves open outcome impact and need for prospective trials.
Cohort (n=166)
No
What is the incidence of and factors associated with switching to a nonstandard nimodipine dosing regimen in patients with aneurysmal subarachnoid hemorrhage?
Nearly half of patients with aneurysmal subarachnoid hemorrhage are switched to an unproven nonstandard nimodipine dosing regimen, primarily driven by the occurrence of vasospasm and vasopressor use.
MacKenzie et al. (2014) conducted a cohort in Aneurysmal subarachnoid hemorrhage (n=166). Nimodipine dosage manipulation vs. Standard nimodipine dosage (60 mg every 4 h) was evaluated on Prescribing incidence of a nonstandard nimodipine dosing regimen (30 mg every 2 h). In patients with aneurysmal subarachnoid hemorrhage, 49% were switched to a nonstandard nimodipine regimen (30 mg every 2 h), with vasospasm (OR 5.30) and vasopressor therapy (OR 3.29) significantly increasing the odds of this manipulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: